European Commission Slaps AstraZeneca With €60M Fine For Patent Abuse
According to a finding by the European Commission, AstraZeneca violated competition rules by blocking or delaying market access for generic versions of Losec and preventing parallel imports of Losec from 1993 to 2000.
The Commission said AstraZeneca had made “misleading” applications to patent offices that gave the firm longer patent protection and exclusive rights.
Moreover, it found that AstraZeneca had...
To view the full article, register now.